Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,768 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Sandborn WJ, et al. Among authors: schreiber s. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13. Clin Gastroenterol Hepatol. 2011. PMID: 21642014 Clinical Trial.
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Lee SD, et al. Among authors: schreiber s. Inflamm Bowel Dis. 2016 Aug;22(8):1870-80. doi: 10.1097/MIB.0000000000000805. Inflamm Bowel Dis. 2016. PMID: 27400222 Free PMC article. Clinical Trial.
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
Loftus EV Jr, Colombel JF, Schreiber S, Randall CW, Regueiro M, Ali T, Arendt C, Coarse J, Spearman M, Kosutic G. Loftus EV Jr, et al. Among authors: schreiber s. Clin Gastroenterol Hepatol. 2016 Dec;14(12):1753-1762. doi: 10.1016/j.cgh.2016.07.019. Epub 2016 Jul 25. Clin Gastroenterol Hepatol. 2016. PMID: 27464588 Free article. Clinical Trial.
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.
D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Kłopocka M, Klaus J, Schreiber S, Il Park D, Hébuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. D'Haens GR, et al. Among authors: schreiber s. Inflamm Bowel Dis. 2022 Jul 1;28(7):1034-1044. doi: 10.1093/ibd/izab215. Inflamm Bowel Dis. 2022. PMID: 34427633 Free PMC article. Clinical Trial.
Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators. Sandborn WJ, et al. Among authors: schreiber s. N Engl J Med. 2007 Jul 19;357(3):228-38. doi: 10.1056/NEJMoa067594. N Engl J Med. 2007. PMID: 17634458 Free article. Clinical Trial.
Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators. Schreiber S, et al. N Engl J Med. 2007 Jul 19;357(3):239-50. doi: 10.1056/NEJMoa062897. N Engl J Med. 2007. PMID: 17634459 Free article. Clinical Trial.
2,768 results